Evaluation of Breast Disorders - Gynecology and Obstetrics - Merck
By A Mystery Man Writer
Description
Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) —dedicated to using leading-edge science to save and improve lives around the world. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge.
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer—Development of Recommendations for Optimal Assay Performance - Modern Pathology
Pooled Analysis of Trastuzumab Deruxtecan Efficacy and Safety by Age in Patients With HER2+ Metastatic Breast Cancer From DESTINY-Breast01, 02, and 03 Trials
PDF) Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel
PDF) Protocol to evaluate sequential electronic health record-based strategies to increase genetic testing for breast and ovarian cancer risk across diverse patient populations in gynecology practices
Breast cancer Nature Reviews Disease Primers
Nipple Discharge: Causes, Symptoms, and Treatment
Cancers, Free Full-Text
PDF) Challenging ChatGPT 3.5 in Senology—An Assessment of Concordance with Breast Cancer Tumor Board Decision Making
PPT - Screening for Breast cancer PowerPoint Presentation, free download - ID:8816564
EBCTCG Meta-analysis of Breast Cancer Recurrence and Survival Following Ovarian Ablation or Suppression in Premenopausal Women
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy - Reinisch - 2023 - Molecular Oncology - Wiley Online Library
What Is Obstetrics and Gynecology?
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Patient-centered risk assessment for ovarian cancer: Individualizing your approach
from
per adult (price varies by group size)